Mouse study identifies gut bacteria molecule that slows heart disease in lab mice

Chinese researchers found a gut bacteria compound that significantly reduces arterial plaque in mice, offering a potential non-drug pathway for heart disease treatment.

Chinese researchers published findings in *Nature* showing that *Bacteroides uniformis* bacteria reduced atherosclerotic plaque burden by 50% in mouse models over 12 weeks. The active molecule—pentadecanoic acid (C15:0)—works by elevating liver LDL receptor expression, which lowers cholesterol and inhibits plaque growth. It also reduced inflammation and macrophage accumulation in plaques. Crucially, C15:0’s effect was weaker than the statin atorvastatin at equivalent dosing (25 mg/kg), and it required functional liver LDL receptors to work. Human relevance is inferred from existing datasets: people with dyslipidemia show lower C15:0 levels than healthy controls, and its production genes are downregulated in heart disease patients.

This mechanism suggests a potential non-drug pathway for heart health through gut microbiome modulation. The study’s significance lies in identifying a specific bacterial metabolite that targets cholesterol metabolism—a process central to atherosclerosis. If translated to humans, it could eventually reduce reliance on statins or other drugs for high cholesterol.

For now, this remains preclinical work. The next step is testing C15:0 in human trials, though its effect strength is weaker than existing statins and mouse models don’t guarantee human relevance. The study’s caveats—requiring metabolically active bacteria, unverified human impact, and weaker efficacy than current drugs—mean this does not yet move abundance. It offers a promising biological pathway, but real-world application remains years away. The potential for cheaper, non-pharmaceutical heart health interventions could eventually reduce medication costs, but only if human trials confirm the mechanism.

Source: Lifespan.io